On August 28, 2026, Coherus Oncology, Inc. entered into a sales agreement with Leerink Partners LLC to offer and sell shares of its common stock through an at-the-market offering program. The company has the right to sell up to $50.0 million in aggregate gross proceeds, though it is not obligated to sell any specific amount. The agent will receive a commission of up to 3.0% of the gross proceeds from each sale. Net proceeds are intended for general corporate purposes, including working capital. This equity issuance represents a material financing event that could dilute existing shareholders and provides liquidity for near-term operations. Coherus Oncology operates in the biotechnology industry, focusing on the development and commercialization of oncology treatments.

On August 12, 2026, Coherus Oncology entered into a Loan and Security Agreement for a $55 million senior secured term loan (Tranche A) maturing in August 2031. The loan carries a floating interest rate of 4.15% plus the greater of the Prime Rate or 6.75%. On August 14, 2026, the company drew the full $55 million to repay its prior senior secured term loan (which matured in May 2029 and had a higher interest rate) and to fund working capital. The company also has options to draw additional tranches of $25 million and $20 million. The loan is secured by substantially all assets, including intellectual property. Coherus Oncology is a biotechnology company that develops and commercializes oncology therapeutics.

Coherus Oncology reported second quarter 2026 financial results with net revenue of $14.3 million, a 37% increase from the prior year period, driven by LOQTORZI sales of $13.6 million. The company posted a GAAP net loss from continuing operations of $33.3 million, or $(0.22) per diluted share, compared to a $44.9 million loss in Q2 2025. Cash and marketable securities stood at $105.3 million as of June 30, 2026. Pipeline updates included completed enrollment for casdozokitug in hepatocellular carcinoma and tagmokitug in head and neck cancer, with initial data readouts expected in the second half of 2026. Coherus Oncology is a commercial-stage biopharmaceutical company focused on developing and marketing innovative oncology therapies.

Coherus Oncology, Inc. announced on June 12, 2026, that its Audit Committee dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm, effective immediately. The company' 's previous reports on consolidated financial statements for fiscal years 2024 and 2024 and the interim period through June 12, 2026, did not contain adverse or disclaimer of opinion. The company also appointed PricewaterhouseCoopers LLP (PwC) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard acceptance procedures. Coherus Oncology, Inc. is a biotechnology company that develops and commercializes oncology products.